Schroders argues immunology’s $216 billion market is being reshaped by precision therapies, biologic-like pills, combination regimens, and early cell-therapy work. The piece frames the shift as more than incremental drug innovation: incumbents’ injection-led franchises face pricing and switching risk as new mechanisms raise efficacy expectations.
Immunology is being rewritten: why this matters for global equity investors
Schroders
John Bowler
Research
8 Pages
Key Takeaways
Market disruption: Immunology generates $216 billion annually, but oral, precision, combination, and cell therapies are reshaping incumbents’ pricing power.
Convenience matters: Schroders identifies five investor considerations, including whether pills can match injections and move earlier in treatment pathways.
Winners need breadth: Schroders highlights three winner traits: late-stage breadth, credible oral/combination strategies, and payer-aware commercial capabilities.